Curve Biosciences Announces Key AI and Clinical Advancements of Whole-Body Intelligence for Chronic Diseases

Curve to present genomic AI foundation model research at the International Conference on Learning Representations (ICLR), held April 23-27, 2026

Liver cirrhosis monitoring study highlighted strong performance of Curve’s Whole-Body Blood Test™ in a real-world setting of 1,482 patients across 23 sites

AI and clinical milestones powered by Whole-Body Intelligence™, proprietary AI models trained on Curve’s Whole-Body Atlas™ for organ-specific biology

SAN MATEO, Calif. & DALLAS--(BUSINESS WIRE)--Curve Biosciences today announced computational and clinical advancements from Whole-Body Intelligence, AI that reveals organ-specific biology in the blood using the company’s Whole-Body Atlas.

Curve deploys Whole-Body Intelligence through Whole-Body Blood Tests that analyze epigenetic patterns within circulating DNA to reveal highly-specific insights into organ health and chronic disease progression through the company’s Whole-Body Atlas – the largest collection of manually-curated tissues characterized by organ and disease state.

Advancements in the company’s genomic AI foundation model were accepted to ICLR (International Conference on Learning Representations), one of the most selective and influential AI conferences, for presentation on April 27, 2026. This work demonstrates that generalist genomic foundation models can be continually pre-trained using data from the Whole-Body Atlas to understand methylation patterns from sequence alone, enabling epigenetic signals to emerge directly in model representations.

More details about Curve’s ICLR presentation:

Presentation title: Methylation-Aware Embedding Geometry Emerges from Bisulfite Pretraining in DNA Language Models

Date: LMRL (Learning Meaningful Representations of Life) Session on April 27, 2026

Presenter: Salwan Butrus, Ph.D., Senior Scientist, Curve Biosciences

In addition, Curve successfully completed a large, multi-center clinical study evaluating its Whole-Body Blood Test in patients with liver cirrhosis, a population with a significant unmet need for effective patient monitoring. The study included 1,482 patients enrolled across 23 clinical sites and represents one of the largest datasets of its kind.

All patient blood samples from this study were analyzed with Whole-Body Blood Tests. Curve’s Whole-Body Intelligence model was first pre-trained on the Whole-Body Atlas and then further trained on blood data from 885 patients in the study. This AI model was finally tested in a fully blinded set of 597 separate patients, showing strong performance in this independent dataset.

“Cirrhosis patients face fragmented and ineffective monitoring approaches, resulting in low adherence and missed opportunities to detect disease progression early,” said Ritish Patnaik, Ph.D., CEO & Co-Founder, Curve Biosciences. “This study shows how Whole-Body Intelligence can transform how chronic liver disease is monitored, enabling earlier detection of disease progression and more precise clinical decision-making.”

Current standard-of-care monitoring for patients with cirrhosis relies on a combination of ultrasound imaging and blood-based protein testing, which is inconsistent and fails to detect early progression. Curve’s Whole-Body Intelligence filters confounding biological noise from the whole body for more accurate blood-based liver cirrhosis monitoring.

“These findings validate our approach of combining high-resolution biological data with advanced AI to unlock clinically meaningful signals from blood,” said Amit Singal, M.D., Chief Medical Officer, Curve Biosciences and Chief of Hepatology at the University of Texas Southwestern Medical Center. “A more accurate, non-invasive monitoring tool has the potential to improve outcomes by identifying disease progression earlier, when disease interventions are most effective.”

Curve is preparing a manuscript for peer-reviewed publication and presentation of the results from this study as part of its path to regulatory and reimbursement approval for its liver cirrhosis monitoring test, while continuing to invest in Whole-Body Intelligence research to build a category-defining company at the nexus of AI and medicine.

About Curve Biosciences

Curve Biosciences® is the Whole-Body Intelligence company. Curve has created the first molecular blueprint of the human body by manually curating the world’s largest collection of comprehensively-characterized tissue samples into its Whole-Body Atlas. Trained on the clarity of this atlas, the company’s Whole-Body Intelligence models identify chronic disease states through its Whole-Body Blood Tests earlier and more accurately than other methods. Curve’s mission is to provide doctors the best intelligence for their patients and to alleviate the pain of chronic diseases by anchoring medicine in biological truth. The company is based in San Mateo, CA and Dallas, TX. For more information, visit www.curvebio.com.